Results 121 to 130 of about 2,156 (171)

Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression: Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR. [PDF]

Purinergic Signal
Shatat AS, Mahgoup EM, Rashed MH, Saleh IG, Akool ES.   +4 more
europepmc   +1 more source

Polarity of hemidesmosome instructive light-curable biosealants guides nascent extracellular matrix for favorable epithelial interactions. [PDF]

Mater Today Bio
Fischer NG, De Jong DA, Evans MD, Aparicio C.   +3 more
europepmc   +1 more source

c-Src-induced vascular malformations require localised matrix degradation at focal adhesions.

J Cell Sci
Essebier P, Keyser M, Yordanov T, Hill B, Yu A, Noordstra I, Yap AS, Stehbens SJ, Lagendijk AK, Schimmel L, Gordon EJ.   +10 more
europepmc   +1 more source

Marimastat alleviates oxidative stress induced cellular senescence by activating autophagy

Biochemical and Biophysical Research Communications, 2022
Marimastat is one of the potent inhibitors of MMP (MMPIs) with few side effects. The impact of marimastat on cellular senescence remains unexplored. Our study evaluated the marimastate effect on oxidative stress-induced cell senescence using NIH3T3 cells.
Jing Xia, Jun Chen, Manoj Kumar Vashisth, Huijie Jia, Hui Hua, Xiaojian Wu, Xiaobo Wang   +6 more
semanticscholar   +4 more sources

Marimastat (BB2516): Current status of development

Cancer Chemotherapy and Pharmacology, 1999
Marimastat (BB-2516) is the first matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed phase I and II trials. Phase I studies involved healthy volunteers who received short courses of marimastat; these were well tolerated.
William P. Steward
semanticscholar   +5 more sources

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

Expert Opinion on Investigational Drugs, 2000
Marimastat (BB-2516) is the first orally bioavailable matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed Phase I, II and some Phase III trials. In Phase I studies, which recruited patients with various malignancies, the main toxicity observed was mild to severe
Anne Thomas, William P. Steward
semanticscholar   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Marimastat in Patients With Advanced Pancreatic Cancer

American Journal of Clinical Oncology, 1999
Patients with solid tumors, including carcinoma of the pancreas, express high levels of matrix metalloproteinases (MMP), and these enzymes are believed to be important for the growth, spread, and dissemination of most solid malignant tumors. Marimastat is the first orally available MMP inhibitor (MMPI) to be tested in humans and has been shown to ...
A, Rosemurgy, J, Harris, A, Langleben, E, Casper, S, Goode, H, Rasmussen   +5 more
openaire   +3 more sources

Synthesis of Marimastat and a Marimastat Conjugate for Affinity Chromatography and Surface Plasmon Resonance Studies

Bioconjugate Chemistry, 2004
Immobilized small-molecule inhibitors are suited for enrichment of biomolecules by affinity chromatography, as it is shown for metalloproteinases and an immobilizable derivative of the hydroxamate-type inhibitor marimastat. A new asymmetric synthesis of marimastat is presented that allows for site-specific attachment to a solid surface, e.g., a ...
Kai Jenssen, Katherina Sewald, Norbert Sewald   +2 more
openalex   +3 more sources

Five-component synthesis of marimastat analogues

Tetrahedron Letters, 1998
Abstract The synthesis of analogues of the matrix metalloproteinase (MMP) inhibitor marimastat has been achieved in one-pot by a two step procedure involving an Ugi four-component reaction followed by hydroxylaminolysis of an acetonide.
Sanjay R. Patel, Lydia Saroglou, C. D. FLOYD, Andrew T. Miller, Mark Whittaker   +4 more
openalex   +2 more sources

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

Journal of Clinical Oncology, 2001
PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer performed to date, compares marimastat, the first ...
S R, Bramhall, A, Rosemurgy, P D, Brown, C, Bowry, J A, Buckels   +4 more
openaire   +3 more sources